Gene editing for hepatitis b: researchers track Long-Term safety
NCT ID NCT07254208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term safety of this gene editing approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICS ARENSIA Exploratory Medicine SRL
Chisinau, Moldova, 2025, Moldova
-
Massachusetts General Hospital/Harvard University
Boston, Massachusetts, 02114, United States
-
New Zealand Clinical Research
Auckland, New Zealand, 1010, New Zealand
-
Queen Mary Hospital, University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.